Shares of Intra-Cellular Therapies Inc (NASDAQ:ITCI) have been given a consensus rating of “Buy” by the thirteen ratings firms that are covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and nine have issued a buy recommendation on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $30.67.
ITCI has been the topic of several research analyst reports. Zacks Investment Research upgraded Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $17.00 target price on the stock in a research note on Wednesday, November 8th. ValuEngine downgraded Intra-Cellular Therapies from a “sell” rating to a “strong sell” rating in a research note on Tuesday, December 5th. SunTrust Banks upgraded Intra-Cellular Therapies from a “hold” rating to a “buy” rating in a research note on Wednesday, November 8th. BidaskClub downgraded Intra-Cellular Therapies from a “sell” rating to a “strong sell” rating in a research note on Tuesday, December 12th. Finally, Canaccord Genuity initiated coverage on Intra-Cellular Therapies in a research note on Friday, December 15th. They set a “buy” rating and a $31.00 target price on the stock.
Shares of Intra-Cellular Therapies (NASDAQ:ITCI) traded down $0.32 during trading hours on Tuesday, hitting $19.65. The stock had a trading volume of 511,568 shares, compared to its average volume of 448,419. Intra-Cellular Therapies has a twelve month low of $7.85 and a twelve month high of $22.67. The stock has a market cap of $1,080.00, a P/E ratio of -8.97 and a beta of 0.87.
Institutional investors have recently bought and sold shares of the business. Russell Investments Group Ltd. purchased a new stake in Intra-Cellular Therapies during the 3rd quarter valued at about $101,000. Quantbot Technologies LP grew its stake in Intra-Cellular Therapies by 233.1% during the 3rd quarter. Quantbot Technologies LP now owns 8,614 shares of the biopharmaceutical company’s stock valued at $135,000 after purchasing an additional 6,028 shares during the last quarter. SG Americas Securities LLC grew its stake in Intra-Cellular Therapies by 45.9% during the 3rd quarter. SG Americas Securities LLC now owns 12,060 shares of the biopharmaceutical company’s stock valued at $190,000 after purchasing an additional 3,794 shares during the last quarter. Voya Investment Management LLC grew its stake in Intra-Cellular Therapies by 16.0% during the 2nd quarter. Voya Investment Management LLC now owns 16,911 shares of the biopharmaceutical company’s stock valued at $210,000 after purchasing an additional 2,338 shares during the last quarter. Finally, Teacher Retirement System of Texas purchased a new stake in Intra-Cellular Therapies during the 4th quarter valued at about $212,000. Institutional investors and hedge funds own 76.93% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Intra-Cellular Therapies Inc (ITCI) Given Consensus Recommendation of “Buy” by Analysts” was posted by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://www.com-unik.info/2018/02/20/intra-cellular-therapies-inc-itci-given-consensus-recommendation-of-buy-by-analysts.html.
Intra-Cellular Therapies Company Profile
Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.